SCHEMBL2234141

SCHEMBL2234141

COc1ccc(S(=O)(=O)Oc2ccc(N3CCNC3=O)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.61
CYP1A1 P04798 5/20 0.48
LMNA P02545 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
TSHR P16473 1/20 0.45
MAOB P27338 1/20 0.44
NPC1 O15118 1/20 0.44
PKM P14618 1/20 0.44
PKLR P30613 1/20 0.44
RAB9A P51151 1/20 0.44
PTGS1 P23219 2/20 0.44
PTGS2 P35354 2/20 0.44
NOX4 Q9NPH5 1/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43
CA7 P43166 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2302983 1.00 GAA (0.61) GAACYP1A1LMNASMN1; SMN2HTT
SCHEMBL2302728 0.91 CYP1A1 (0.58) GAACYP1A1LMNASMN1; SMN2HTT
SCHEMBL2235106 0.89 LMNA (0.56) GAACYP1A1LMNASMN1; SMN2HTT
SCHEMBL2303056 0.89 LMNA (0.56) GAACYP1A1LMNASMN1; SMN2HTT
SCHEMBL2300751 0.88 GAA (0.46) GAACYP1A1LMNASMN1; SMN2HTT
SCHEMBL2307065 0.88 GAA (0.46) GAALMNASMN1; SMN2NPC1RAB9A
SCHEMBL2300655 0.87 CYP1A1 (0.50) GAACYP1A1LMNASMN1; SMN2HTT
SCHEMBL2884739 0.87 HTR3E (0.51) GAALMNASMN1; SMN2HTTNPC1
SCHEMBL2303527 0.86 GAA (0.45) GAACYP1A1LMNASMN1; SMN2HTT
SCHEMBL2297976 0.86 TDP1 (0.51) GAACYP1A1LMNASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 GAA 3894/4885CYP1A1 1777/4885LMNA 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.